Literature DB >> 14663302

Does early immunotherapy reduce the conversion of ocular myasthenia gravis to generalized myasthenia gravis?

Mark J Kupersmith.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 14663302     DOI： 10.1097/00041327-200312000-00001

Source DB:  PubMed          Journal:  J Neuroophthalmol        ISSN： 1070-8022            Impact factor:   3.042


× No keyword cloud information.
  3 in total

1.  Safety of prednisone for ocular myasthenia gravis.

Authors:  Beau B Bruce; Mark J Kupersmith
Journal:  J Neuroophthalmol       Date:  2012-09       Impact factor: 3.042

2.  miR-30e-5p as predictor of generalization in ocular myasthenia gravis.

Authors:  Liis Sabre; Paul Maddison; Sui H Wong; Girija Sadalage; Philip A Ambrose; Gordon T Plant; Anna R Punga
Journal:  Ann Clin Transl Neurol       Date:  2019-01-24       Impact factor: 4.511

Review 3.  Circulating miRNAs as Potential Biomarkers in Myasthenia Gravis: Tools for Personalized Medicine.

Authors:  Liis Sabre; Tanel Punga; Anna Rostedt Punga
Journal:  Front Immunol       Date:  2020-03-04       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.